Precision Sells Off Autoimmune Rights For Allogeneic CAR-T To TG Therapeutics

 
• By Alaric DeArment

TG, which has seen growing sales for Briumvi in multiple sclerosis, is expanding into CAR-T for immunology as Precision pivots to in vivo gene therapies.

TG and Precision signed a deal for Precision's off-the-shelf CAR-T, both companies having recently made strategic pivots. • Source: Shutterstock

More from Deals

More from Business